SEC Form 4 · accession 0001493152-26-040238
Vivos Therapeutics, Inc. · VVOS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bradford K. Amman
Officer — Principal Accounting Officer
Period of report
Jul 31, 2026
Accepted (ET)
Aug 26, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001716166
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 31, 2026 | A | 250,000 | $0.41 | A | 250,080 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.41 | Jul 31, 2026 | A | 150,000 | A | — | Jul 31, 2036 | Common Stock | 150,000 | 326,533 | D |
Explanation of responses
- F1On July 31, 2026 (the "Grant Date"), the Reporting Person received a grant of 150,000 stock options, which grant was made under the Issuer's 2024 Omnibus Equity Incentive Plan. Stock options shall vest and become exercisable at the rate of 25,000 shares per month from November 1, 2026 through April 1, 2026.